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Abstract 
Background: Non‑small cell lung cancer comprises the majority of lung cancer cases and is insensitive to chemo‑
therapy. Most patients develop drug resistance. Recently, tetrandrine (TET), a bis‑benzylisoquinoline alkaloid, was 
identified as a novel anti‑cancer agent. However, the effect of tetrandrine combined with cisplatin on lung cancer has 
not yet been studied. We aimed to identify a possible synergistic effect between tetrandrine and cisplatin, besides, 
to investigate the effects of TET in combination with DDP on proliferation and apoptosis in cisplatin‑resistant and 
cisplatin‑sensitive A549 cell lines, and to study the underlying mechanism.
Methods: Cell viability was confirmed with CCK8 assays, and the IC50 values for each treatment group were cal‑
culated. The synergistic interaction of these drugs was evaluated using an isobolographic analysis. Proliferation 
was assessed by EDU staining. Hoechst staining and flow cytometry were used to assess apoptosis. Apoptosis‑ and 
autophagy‑associated proteins were analyzed by western blot. Transmission electron microscopy was used to detect 
autophagy, RFP‑GFP‑LC3 lentivirus was used to perform autophagic flux assay.
Results: Tetrandrine and cisplatin exerted synergistic cytotoxic effects on both cisplatin‑resistant and cisplatin‑
sensitive A549 cell lines. The combination of tetrandrine and cisplatin induced apoptosis and inhibited proliferation 
in a synergistic manner. The formation of autophagosomes was evident by transmission electron microscopy. The 
autophagic flux of combination treatment was increased.
Conclusions: Tetrandrine synergized with cisplatin to reduce the viability of cisplatin‑resistant and cisplatin‑sensitive 
A549 cells, tetrandrine could reverse the resistance of A549 cells to cisplatin. Tetrandrine combined with cisplatin 
could induce autophagy. Therefore, tetrandrine is a potent autophagy agonist and may be a promising drug for the 
treatment of non‑small cell lung cancer.
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Background
Lung cancer is one of the most common malignant 
tumors and remains the leading cause of cancer-related 
death worldwide. Non-small cell lung cancer (NSCLC) 
comprises the majority of lung cancer cases [1]. The 
most powerful prognosticator of clinical outcome for 
patients with NSCLC is the response to neoadjuvant 
chemotherapy. Although this is the best available at pre-
sent, it remains impossible to predict which patients 
will respond to chemotherapy. Moreover, most NSCLC 
tumors develop drug resistance [2]. Because cisplatin-
based chemotherapy has been the first-line treatment 
for NSCLC in the clinic [3], the effect of cisplatin on 
lung cancer has been widely studied. It has been shown 
that the anticancer effect of cisplatin depends on its abil-
ity to generate irreparable DNA lesions. However, the 
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clinical responses elicited by cisplatin in lung cancer 
patients usually vanish because of resistance to the cyto-
toxic activity of cisplatin [4–7]. Therefore, new drugs are 
required to reverse acquired drug resistance to improve 
survival and quality of life. Previous studies have shown 
that several plant polyphenols can achieve this goal [8, 9].
In recent years, tetrandrine (TET) has garnered 
increasing attention due to its potential use as a novel 
anticancer agent either alone or in combination with 
other chemotherapeutic drugs [10–16]. TET, a bis-
benzylisoquinoline alkaloid that is extracted from the 
root tuber of the Chinese herb Stephania tetrandra S. 
Moore, has been widely used to treat arthritis, arrhyth-
mia, inflammation, silicosis and various types of cancer 
[17–19]. Studies have demonstrated that TET can cause 
cell-cycle arrest and induce apoptosis in A549 human 
lung carcinoma cells [20]. Moreover, the inhibition of 
extracellular signal-regulated kinase (ERK) synergisti-
cally enhanced TET-induced apoptosis in A549 cells [21]. 
However, whether TET enhances the efficacy of chemo-
therapy against lung cancer remains to be elucidated. In 
this study, we investigated the synergistic effects between 
TET and cisplatin.
Apoptosis and autophagy control basic cellular metab-
olism. All tumor cells undergo apoptosis, which is also 
known as programmed cell death, especially in the vicin-
ity of tumor necrosis. Most chemotherapy drugs rely on 
the induction of apoptosis for efficacy [22]. Autophagy is 
a cellular pathway involved in protein and organelle deg-
radation in the lysosome that serves as a type of cellular 
renovation. Three types of autophagy have been identi-
fied: macro-autophagy, micro-autophagy and chaper-
one-mediated autophagy [23]. Autophagic dysfunction 
is associated with several pathological processes, such 
as cancer, microbial infection, aging and neurodegen-
eration [24]. Several synthetic chemotherapeutic agents 
induce autophagic cell death in a variety of cancer cells. 
Autophagy was recently shown to block the induction 
of apoptosis, and apoptosis-associated activation was 
shown to deactivate the autophagic process. Paradoxi-
cally, autophagy may also help induce apoptosis in some 
cases [25]. Therefore, autophagy and the relationship 
between apoptosis and autophagy need to be further 
explored to manipulate these pathways for the treatment 
of human disease.
Thus, we aimed to identify possible synergism between 
TET and cisplatin; furthermore, we sought to investigate 
the effects of TET in combination with DDP on prolif-
eration and apoptosis in cisplatin-resistant and cisplatin-
sensitive A549 cell lines, and to find the role of autophagy 
in the drug treatments.
Results
TET and cisplatin display independent 
and synergistic cytotoxicity against cisplatin‑resistant 
and cisplatin‑sensitive A549 cells
To determine the effect of TET and DDP on cell viabil-
ity, cells treated with different concentrations of the two 
drugs (TET: 0.5–8  µg/ml; DDP: 6.25–100  µM) for 48  h 
were subjected to a CCK8 assay. The IC50 of each agent 
was calculated using dose–response curves (Fig.  1). 
Based on the IC50 of TET, two low doses (0.25 and 0.5 µg/
ml) were selected for combination treatments with DDP. 
Isobolograms were generated using the IC50 values 
(Fig. 2). Both DDP and TET dose-dependently inhibited 
viability. Compared with DDP treatment alone, the com-
bination treatment significantly reduced cell viability, and 
the isobolograms illustrated the significant synergistic 
effect of the combination treatment. These data suggest 
that TET could partially reverse cisplatin resistance.
TET increased the cisplatin‑induced inhibition 
of proliferation in cisplatin‑resistant and cisplatin‑sensitive 
A549 cells
To determine the effect of TET and DDP on proliferation, 
we exposed cisplatin-resistant and cisplatin-sensitive 
A549 cells to TET alone, DDP alone or their combination 
for 12 h. EDU staining was performed to detect prolifer-
ating cells. As shown in Fig. 3, compared with the control 
group and the DDP group, cell proliferation decreased 
significantly when TET was combined with DDP 
(p < 0.05). Furthermore, the cell lysates were analyzed by 
western blot to evaluate the expression of proliferation-
related proteins (Fig. 6). The combination treatment sig-
nificantly decreased p-Akt expression.
TET enhanced cisplatin‑mediated apoptosis 
in cisplatin‑resistant and cisplatin‑sensitive A549 cells
To further evaluate the effect of TET on DDP-mediated 
apoptosis, cisplatin-resistant and cisplatin-sensitive A549 
cells were treated as described above. Hoechst staining 
and annexin V/propidium iodide (PI) staining were per-
formed to observe apoptosis. Western blot analysis was 
used to investigate the levels of intracellular apoptosis-
related proteins. Figures 4 and 5 show that the apoptosis 
rate in response to treatment with DDP alone or the com-
bination was significantly higher than that in response to 
treatment with control or TET alone (p < 0.05). Moreo-
ver, the combination treatment increased apoptosis 
compared with DDP treatment alone (p  <  0.05). In the 
combination treatment group, Bax and cleaved-caspase 
3 were upregulated, whereas Bcl-2 was downregulated 
(Fig. 6).
Page 3 of 10Ye et al. Cancer Cell Int  (2017) 17:40 
Autophagy and autophagic flux detection in each 
treatment group
Western blot analysis was used to determine the 
expression of the autophagy marker protein LC3. Fig-
ure  7 shows that the production of LC3 significantly 
increased in combination treatment group. To further 
confirm the occurrence of autophagy, the formation of 
autophagosomes was directly observed using transmis-
sion electron microscopy (TEM) (Fig. 8). Besides, Fig. 9 
shows that the autophagic flux was increased in combi-
nation treatment. Taken together, these observations 
indicated that TET could significantly increase autophagy 
when combined with DDP.
Fig. 1 Dose‑response curves of DDP, TET and the combination treatment. Cisplatin‑resistant (a) and cisplatin‑sensitive (b) A549 cells were treated 
with different concentrations of the two drugs (TET: 0.5–8 µg/ml; DDP: 6.25–100 µM) for 48 h. The concentration of TET in the combination treat‑
ment was 0.25 µg/ml. C and D are the IC50 values of DDP and combination treatment. *p < 0.05 versus the DDP treatment (n = 3)
Fig. 2 Isobolographic analysis of the cytotoxic effect of the combination treatment on the two cell lines. a The synergistic effect of the combina‑
tion treatment on cisplatin‑resistant A549 cells. b The synergistic effect of the combination treatment on cisplatin‑sensitive A549 cells. The solid and 
hollow dots represent the IC50 values of the combination treatments at 0.25 and 0.5 µg/ml TET, respectively
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Discussion
Our research demonstrated that TET dose-dependently 
inhibited the viability of cisplatin-resistant and cisplatin-
sensitive A549 cells and increased the sensitivity of cis-
platin-resistant A549 cells to cisplatin. Previous studies 
have shown that TET can induce apoptosis by activating 
caspase-3 in lung carcinoma cells [20]. Our study showed 
that DDP treatment alone downregulated the expression 
of Bcl2 and upregulated the expression of Bax, indicat-
ing that DDP can induce caspase-dependent apoptosis, 
when combined with TET, this effect is more obvious. 
Compared with DDP treatment alone, the combination 
of TET and DDP significantly decreased A549 cell prolif-
eration and increased apoptosis. These data suggest that 
TET synergizes with DDP in both cell lines and that the 
anti-cancer effect depends on the inhibition of prolifera-
tion and the promotion of apoptosis.
In addition, the combination treatment downregulated 
the expression of p-Akt, suggesting that the synergistic 
effect was accompanied by the inhibition of the PI3K/
Fig. 3 Influence of each treatment on cell proliferation. a EDU staining of cisplatin‑resistant A549 cells after various treatments (×200). The concen‑
trations of DDP and TET were 60 µM and 0.25 µg/ml, respectively. b EDU staining of cisplatin‑sensitive A549 cells (×200). The concentrations of DDP 
and TET were 25 µM and 0.25 µg/ml, respectively. The time of the drug treatments was 12 h. c, d are the statistical analyses of a, b. *p < 0.05 versus 
the control cells; #p < 0.05 versus DDP treatment (n = 3)
Fig. 4 Influence of each treatment on apoptosis. a Hoechst staining of cisplatin‑resistant A549 cells after various treatments (×200). The concentra‑
tions of DDP and TET were 60 µM and 0.25 µg/ml, respectively. b Hoechst staining of cisplatin‑sensitive A549 cells (×200). The concentrations of 
DDP and TET were 25 µM and 0.25 µg/ml, respectively. The time of the drug treatments was 12 h. c, d are the statistical analyses of a, b. *p < 0.05 
versus the control cells; #p < 0.05 versus DDP treatment (n = 3)
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Akt signaling pathway. The PI3K/Akt pathway is neces-
sary for the regulation of various biological processes, 
such as survival, proliferation, apoptosis and differentia-
tion [26]. Thus, many anticancer therapeutic strategies 
have focused on blocking this pathway. Earlier studies 
have shown that PI3K/Akt signaling pathway activation 
is closely related to drug resistance [27, 28]. TET can 
repress Akt activity in cancer cells; thus, TET, a type of 
PI3K/Akt inhibitor, may be used to develop new anti-
cancer treatment strategies.
Apoptosis serves as a natural barrier to the develop-
ment of cancer [29]. Previous studies have shown that the 
resistance of NSCLC cells to various cytotoxic therapies 
may be due to a defect in apoptosis signaling [30]. Bcl-2 
Fig. 5 Apoptosis induced by each treatment for 12 h on cisplatin‑resistant A549 cells (a) and cisplatin‑sensitive A549 cells (b). The apoptotic cells 
include both early apoptotic and late apoptotic cells. a The concentrations of DDP and TET were 60 µM and 0.25 µg/ml, respectively. b The concen‑
trations of DDP and TET were 25 µM and 0.25 µg/ml, respectively. c, d are the statistical analyses of a, b. *p < 0.05 versus the control cells, #p < 0.05 
versus the DDP treatment (n = 3)
Fig. 6 The expression of proliferation‑ and apoptosis‑related proteins of the cells in response to different treatments for 12 h. a Proteins expression 
of cisplatin‑resistant A549 cells after each drug treatment. The concentrations of DDP and TET were 60 µM and 0.25 µg/ml, respectively. b Proteins 
expression of cisplatin‑ sensitive A549 cells. The concentrations of DDP and TET were 25 µM and 0.25 µg/ml, respectively. c–e are the statistical 
analyses of a, besides, f–h are the statistical analyses of b. *p < 0.05 versus the control cells, #p < 0.05 versus the DDP treatment (n = 3)
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Fig. 7 LC3 II protein expression levels of cisplatin‑resistant A549 cells (a) and cisplatin‑sensitive A549 cells (b). The concentrations of DDP in a, b 
were 60 and 25 µM, respectively. The concentrations of TET was 0.25 µg/ml. The time of the drug treatments was 12 h. c, d are the statistical analy‑
ses of a, e and f are the statistical analyses of b. *p < 0.05 versus the control cells, #represents p < 0.05 versus the DDP treatment (n = 3)
Fig. 8 TEM images of autophagosomes. Autophagy induced by each treatment in cisplatin‑resistant A549 cells (a) and cisplatin‑sensitive A549 cells 
(b). The concentrations of DDP in a, b were 60 and 25 µM, respectively. The concentration of TET was 0.25 µg/ml. The time of the drug treatments 
was 12 h. The scale bars represent 500 nm, and the arrows indicate the autophagosomes. c, d are the statistical analyses of a, b. *p < 0.05 versus the 
control cells, #p < 0.05 versus the DDP treatment (n = 3)
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family proteins play a pivotal role in the regulation of 
apoptosis. Some reports have indicated that the absence 
of Bax blocks apoptosis and increases drug resistance 
[31]. We found that the expression of the pro-apoptotic 
protein Bax was upregulated and that the expression 
of the anti-apoptotic protein Bcl-2 was decreased in 
DDP-treated cells. The combination of TET and DDP 
enhanced this effect, suggesting that TET could enhance 
cisplatin-mediated apoptosis via the Bax/Bcl-2 path-
way, which reversed the resistance of cisplatin-resistant 
A549 cells. The relationship between Bax/Bcl-2 and drug 
resistance needs to be further investigated.
Because apoptosis is the most common target of chem-
otherapy, the significance of autophagy in antitumor 
management has not received considerable attention 
[32]. However, over the past decade, interest in the roles 
of autophagy in human health and disease has become 
widespread [33]. Autophagy, meaning “self-eating,” is 
a cellular degradation pathway in which cytoplasmic 
cargos are delivered to the lysosome, and intracellular 
components are recycled. Autophagy occurs at low lev-
els in almost all cells, but it is rapidly upregulated when 
cells need to generate nutrients and energy, such as dur-
ing starvation, high bioenergetic demand or growth fac-
tor withdrawal [34]. To some extent, it represents cellular 
adaptation to stress and serves as a protective mecha-
nism. However, autophagy is a double-edged sword, 
and it is now widely implicated in pathophysiological 
processes, such as cancer. Autophagy may influence the 
initiation and progression of cancer as well as therapeu-
tic interventions [35]. Previous studies have indicated 
that autophagy results in the excessive degradation of 
the cytoplasm, leading to a form of non-apoptotic pro-
grammed cell death called ‘autophagic’ cell death [36]. As 
described above, our research showed that the expression 
of the autophagy marker protein LC3-II was upregulated 
and the autophagic flux was increased by the combina-
tion treatment, autophagosome formation was observed 
by TEM. These results suggest that drug treatment could 
induce autophagy and that autophagy may participate in 
Fig. 9 Autophagic flux assay of cisplatin‑resistant A549 cells (a) and cisplatin‑sensitive A549 cells (b) (×400). The concentrations of DDP in a, b were 
60 and 25 µM, respectively. The concentration of TET was 0.25 µg/ml. The time of the drug treatments was 12 h. Yellow arrows point to autophago‑
somes and red arrows point to autolysosomes. c, d are the statistical analyses of a, b. *p < 0.05 versus the control cells, #p < 0.05 versus the DDP 
treatment (n = 3)
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the resistance of cells to cisplatin. These details need to 
be elucidated in future studies, for example, autophagy 
inhibitor or genetic approach to knockdown or knockout 
core Atgs could be used to verify the role of autophagy in 
the drug treatments.
Recent years, more and more researches study the rela-
tionship between autophagy and apoptosis. Autophagy 
and apoptosis may occur concurrently in a cell, and 
autophagy can facilitate the activation of apoptosis in 
some cases, though it suppresses apoptosis in most 
instances [36]. Individual genes, such as ATG genes, 
may play an essential role in the pro-apoptotic signaling 
pathway [37]. Autophagy may stimulate apoptosis via the 
formation of autophagosomes, and this process plays an 
important role in the activation of caspase-8 [38]. More-
over, autophagy can deplete endogenous inhibitors of 
apoptosis to trigger this cell death pathway [36]. LC3 is a 
major regulator of autophagosome formation; we found 
that the combination treatment upregulated LC3-II, 
which indicated that autophagy may stimulate apoptosis 
via the formation of autophagosomes. Some studies have 
shown that the Bcl-2 family of proteins also plays a vital 
role in autophagy regulation and that Bcl-2 can inhibit 
autophagy [39]. Our research showed that the combi-
nation treatment downregulated Bcl-2 expression, thus 
supporting the role of Bcl-2 family proteins in autophagy. 
The relationship between these two types of cell death is 
complex, and autophagy-apoptosis crosstalk has a broad 
pathophysiological influence. Therefore, an improved 
understanding of these pathways may help to yield addi-
tional therapeutic targets for lung cancer.
Other studies have demonstrated that TET induces the 
accumulation of reactive oxygen species (ROS) [40], and 
the generation of ROS plays an important role in the reg-
ulation of apoptosis and autophagy [41, 42]. The results 
described herein may only represent part of the effect of 
TET. Further studies are essential to better understand 
these molecular mechanisms and to obtain new targets 
for cancer treatment.
Conclusions
In our study, we discovered that TET increased the sensi-
tivity of cisplatin-resistant A549 cells to cisplatin, and the 
combination of TET and DDP inhibited cell proliferation 
while increasing apoptosis. Additionally, the combination 
treatment could induce autophagy. All of these findings 




The cells were purchased from the Institute of Bio-
chemistry and Cell Biology of the Chinese Academy of 
Sciences (Shanghai, China). The cells were propagated in 
RPMI 1640 medium (GIBCO BRL) supplemented with 
10% fetal bovine serum, 100 U/ml penicillin and 100 U/
ml streptomycin at 37 °C in a 5% CO2 humidified atmos-
phere. To maintain the resistance of cisplatin-resistant 
A549 cells, 2  µg/ml cisplatin was added to the medium 
for these cells. The cells were cultured in complete 
medium without cisplatin for 3  days before any experi-
ment was performed.
Reagents
TET was kindly provided by Zhejiang Haizheng Pharma-
ceutical Co., Ltd. Cisplatin was obtained from the First 
Affiliated Hospital of Nanjing Medical University. The 
EDU and Hoechst staining solutions were purchased 
from Guangzhou RiboBio Co. (Guangzhou, China). The 
annexin V-fluorescein isothiocyanate (FITC) kit was pur-
chased from Bender MedSystems (Vienna, Austria). The 
RFP-GFP-LC3 lentivirus was purchased from Shanghai 
Genechem Co., Ltd.
Cell viability assay
Cell viability was measured using a CCK8 assay kit 
(Obio Technology (Shanghai) Co., Ltd.). The cells 
(1 × 103 cells/well) were seeded in 96-well plates, grown 
overnight, and then treated with the indicated concen-
trations of different drugs for 48 h. Subsequently, 10 µl 
of CCK8 solution was added to each well, and the plates 
were incubated for 1  h. The absorbance was measured 
at 450 nm using a microplate reader (BioTek, Winooski, 
VT, USA).
Isobolographic analysis
Synergism between TET and DDP was evaluated with an 
isobolographic analysis. Briefly, the doses of TET were 
plotted on the x-axis, and the doses of DDP were plot-
ted on the y-axis; points representing equal effects on cell 
viability were connected to obtain an isobologram. The 
50% inhibitory concentration (IC50) of TET plotted on 
the x-axis was connected to that of DDP plotted on the 
y-axis to obtain a straight line. Points on, below or above 
the line indicated an additive, synergistic or antagonistic 
effect, respectively.
EDU staining for cell proliferation
The cells were treated with different drugs, washed three 
times with PBS, and then stained with 300 µl of staining 
solution for 2 h according to the manufacturer’s protocol. 
After an additional three washes with PBS, the cells were 
examined with a fluorescence microscope (Olympus, 
Japan). Proliferating cells were identified by red stain-
ing, and the number of proliferating cells in ten different 
fields was counted.
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Hoechst 33342 staining for apoptosis analysis
The cells were seeded on microscope slides (Millipore, 
USA) and treated with different drugs for 12  h. After 
three washes with PBS, the cells were incubated with 
Hoechst staining buffer for 10 min at room temperature 
in the dark. The percentage of cells undergoing apopto-
sis was then determined with a fluorescence microscope 
(Olympus, Japan). Apoptotic cells were identified by 
bright blue staining, and the number of apoptotic cells in 
ten different fields was counted.
Apoptosis assay by flow cytometry
The cells were harvested after drug treatment, washed 
with PBS, and then stained with annexin V-FITC and PI 
according to the manufacturer’s protocol. After incuba-
tion in the dark for 15 min, the cells were analyzed using 
a FACScan flow cytometer (Becton–Dickinson, CA, USA).
Western blot analysis
The cells were harvested and lysed in RIPA lysis buffer 
(Thermo Scientific, Rockford, IL, USA) supplemented 
with a protease inhibitor cocktail (Roche, Indianapo-
lis, IN, USA). Protein from each sample was resolved by 
10% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to polyvinylidene 
fluoride (PVDF) membranes (Millipore, Billerica, MA, 
USA). The membranes were blocked with 5% nonfat 
milk (Bio-Rad) in Tris-buffered saline containing 0.1% 
Tween 20 (TBST) at room temperature for 1 h and then 
incubated with anti-pAKT (1:1000, Cell Signaling Tech-
nology, Inc., Beverly, MA, USA), anti-AKT (1:1000, Cell 
Signaling Technology), anti-Bax (1:1000, Cell Signaling 
Technology), anti-Cleaved caspase 3 (1:1000, Cell Signal-
ing Technology), anti-Bcl-2 (1:1000, Abcam, Cambridge, 
UK), anti-glyceraldehyde-3 phosphate dehydrogenase 
(GAPDH) (1:5000; Bioworld, Nanjing, China) primary 
antibody at 4 °C overnight. After washing with TBST, the 
membranes were incubated with HRP-conjugated sec-
ondary antibody for 1 h at room temperature. Following 
three additional washes with TBST, the protein bands of 
interest were visualized using enhanced chemilumines-
cence detection reagents (Thermo) and the Bio-Rad Gel 
Doc/ChemiDoc Imaging System and then analyzed using 
Quantity One software.
Transmission electron microscopy analysis and autophagic 
flux assay
Standard TEM was conducted to analyze cellular ultras-
tructure. Approximately 12  h after drug treatment, the 
cells were fixed and embedded. Thin sections (90  nm) 
were examined at 80  kV with a JEOL 1200EX trans-
mission electron microscope. Approximately 15 cells 
were counted, and autophagosomes were defined as 
double-membrane vacuoles measuring 0.5 or 200  µm. 
The cells were seeded on the culture plate, and moderate 
RFP-GFP-LC3 lentivirus were added to the plate accord-
ing to the instructions, the cells were propagated in RPMI 
1640 medium supplemented with 10% fetal bovine serum, 
100 U/ml penicillin and 100 U/ml streptomycin at 37 °C 
in a 5% CO2 humidified atmosphere for 72  h. Then the 
cells transfected with RFP-GFP-LC3 lentivirus were 
treated with different drugs for 12 h, and analysed by laser 
confocal microscope (ZEISS LSM, German).
Statistical analysis
All of the experiments were performed at least three 
times. Data are presented as the mean ±  SD. All of the 
statistical analyses were performed using one-way analy-
sis of variance (ANOVA) followed by Dunnett’s post hoc 
test employing Prism 6.00 software (GraphPad Software, 
San Diego, CA, USA) and SPSS version 20 (SPSS Inc., 
Chicago, IL, USA). P < 0.05 was considered to indicate a 
significant difference.
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